SAM #75N98026Q01002

Genetic Testing and Next Generation Sequencing Services for Hematologic Disorders

This opportunity from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), seeks specialized genetic testing and next generation sequencing services for hematologic disorders. - Government Buyer: - National Heart, Lung, and Blood Institute (NHLBI), Division of Intramural Research (DIR), Clinical Division - OEMs and Vendors: - The University of Chicago Medical Center (service provider) - Illumina (sequencing technology referenced) - Services Requested: - Validated Next Generation Sequencing assay covering approximately 111 genes related to inherited bone marrow failure syndromes, aplastic anemia, myeloid neoplasms, clonal hematopoiesis, and other hematologic disorders - Includes specimen collection kits, specimen processing, sequencing, quality control, bioinformatics analysis, supplemental Sanger sequencing, clinical reporting, secure electronic report access, and technical consultation - Unique Requirements: - Testing must be performed at a CLIA-certified laboratory (University of Chicago Genetics Services Laboratory) - Use of Illumina or equivalent sequencing technology - Secure electronic reporting and orthogonal confirmation of results - Services are critical for patient management and ongoing clinical trials - Period of Performance: - One-year base period with four one-year option years (up to five years total) - No specific product part numbers or quantities are provided; the focus is on comprehensive service delivery

Description

See attached Notice of Intent and Statement of Work for details.

View original listing